The DOI matches its Crossref record.
Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial
Open accessAbstract
BACKGROUND: Leukotrienes produced by the 5-lipoxygenase pathway of arachidonic acid metabolism may mediate bronchoconstriction and inflammatory changes important in the pathophysiology of asthma. Leukotriene inhibition may be effective in asthma management. OBJECTIVE: This clinical trial was performed to assess the long-term efficacy and safety of zileuton, an inhibitor of 5-lipoxygenase. METHODS: In this multicenter, double-blind, parallel-group, placebo-controlled trial, 600 mg of zileuton, 400 mg of zileuton, or placebo was given orally, each four times daily for 6 months. Patients with mild to moderate asthma (n = 373), 18 to 62 years of age, being managed with regularly inhaled beta-agonist alone, were randomized to the zileuton or placebo groups (n = 122 to 126). Outcome measures included serial spirometry, daily peak expiratory flow rates, daytime and nocturnal symptoms, frequency of beta-agonist use, and number of asthma exacerbations treated with systemic corticosteroids. RESULTS: An acute bronchodilatory effect was observed 2 to 5 hours after the initial dose of medication in both 400 mg zileuton and 600 mg zileuton groups compared to the placebo group. Both zileuton groups had significantly greater improvements in FEV1 than did the placebo group by day 8. On day 36, FEV1 improved 16% and 12% from baseline for patients treated with 600 mg zileuton and 400 mg zileuton, respectively, compared with an improvement of 6% for the placebo-treated group (p < 0.01, zileuton 600 mg vs placebo). Blood eosinophil levels were significantly reduced in both zileuton-treated groups compared with the placebo group. In the group receiving 600 mg zileuton, morning peak expiratory flow rate improved by 7% to 10%; daytime and nocturnal symptoms decreased by 37% and 31%, respectively; beta-agonist use decreased by 31%; and the proportion of patients requiring steroid rescue medication during the study was reduced by 62% (p < 0.05 for all comparisons of zileuton, 600 mg, vs placebo). Improvements were sustained over 6 months. Adverse events were similar in the three groups with no apparent, dose-related side effects. CONCLUSION: Zileuton produces objective and subjective improvements in patients with mild to moderate asthma and is well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment of Asthma with Drugs Modifying the Leukotriene Pathway
Drazen, J. M., Israel, E., & O'Byrne, P. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400306 · Cited by 820
DAHLÉN, B., NIZANKOWSKA, E., SZCZEKLIK, A., ZETTERSTRÖM, O., BOCHENEK, G., KUMLIN, M., MASTALERZ, L., PINIS, G., SWANSON, L. J., BOODHOO, T. I., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707089 · Cited by 396
Self-citationSzefler, S. J., Wenzel, S., Brown, R., Erzurum, S. C., Fahy, J. V., Hamilton, R. G., Hunt, J. F., Kita, H., Liu, A. H., Panettieri, R. A., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.979 · Cited by 395
Doherty, T. A., Khorram, N., Lund, S., Mehta, A. K., Croft, M., & Broide, D. H. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.048 · Cited by 393
Chauhan, B. F., & Ducharme, F. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002314.pub3 · Cited by 306
Metadata
- Authors
- Liu, M. C., Dubé, L. M., & Lancaster, J.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 1996-11
- Volume
- 98
- Issue
- 5
- Pages
- 859-871
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W1975272363
- Cited by
- 249
- References
- 0
- FWCI
- 14.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. https://app.cochat.ai/papers/10.1016/s0091-6749(96)80002-9
- The paper
- Liu, M. C., Dubé, L. M., & Lancaster, J. (1996). Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/s0091-6749(96)80002-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.